Do analysts rate MDCX or PULM?

Medicus Pharma presently has a consensus target price of $9.00, suggesting a potential upside of 2,116.75%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Medicus Pharma is more favorable than Pulmatrix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Pulmatrix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MDCX or PULM more profitable?

Pulmatrix's return on equity of -107.84% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Medicus Pharma N/A -3,137.84% -311.33% Pulmatrix N/A -107.84% -91.58%

Does the media favor MDCX or PULM?

In the previous week, Medicus Pharma had 2 more articles in the media than Pulmatrix. MarketBeat recorded 5 mentions for Medicus Pharma and 3 mentions for Pulmatrix. Medicus Pharma's average media sentiment score of 1.17 beat Pulmatrix's score of 0.30 indicating that Medicus Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medicus Pharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pulmatrix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PULM or SKYE?

Skye Bioscience has a consensus price target of $8.50, indicating a potential upside of 1,252.21%. Given Skye Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Skye Bioscience is more favorable than Pulmatrix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pulmatrix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Skye Bioscience 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is PULM or SKYE more profitable?

Pulmatrix's return on equity of -107.84% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Pulmatrix N/A -107.84% -91.58% Skye Bioscience N/A -217.27% -162.39%

Does the media refer more to PULM or SKYE?

In the previous week, Pulmatrix and Pulmatrix both had 3 articles in the media. Skye Bioscience's average media sentiment score of 0.47 beat Pulmatrix's score of 0.30 indicating that Skye Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulmatrix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Skye Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PULM or ALVR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pulmatrix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, PULM or ALVR?

Pulmatrix has higher revenue and earnings than AlloVir. Pulmatrix is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulmatrix $7.81M 0.75 -$5.16M -$1.23 N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is PULM or ALVR more profitable?

AlloVir's return on equity of -71.03% beat Pulmatrix's return on equity. Company Net Margins Return on Equity Return on Assets Pulmatrix N/A -107.84% -91.58% AlloVir N/A -71.03% -61.27%

Do analysts rate PULM or AYTU?

Aytu BioPharma has a consensus price target of $10.75, indicating a potential upside of 397.69%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Aytu BioPharma is more favorable than Pulmatrix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pulmatrix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aytu BioPharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is PULM or AYTU more profitable?

Pulmatrix has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat Pulmatrix's return on equity. Company Net Margins Return on Equity Return on Assets Pulmatrix N/A -107.84% -91.58% Aytu BioPharma -60.17% -69.93% -13.25%

Do analysts rate NRSN or PULM?

NeuroSense Therapeutics currently has a consensus target price of $8.50, indicating a potential upside of 1,110.31%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Pulmatrix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroSense Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Pulmatrix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NRSN or PULM more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat Pulmatrix's return on equity. Company Net Margins Return on Equity Return on Assets NeuroSense Therapeutics N/A N/A N/A Pulmatrix N/A -107.84% -91.58%

Does the media prefer NRSN or PULM?

In the previous week, Pulmatrix had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 3 mentions for Pulmatrix and 2 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 1.40 beat Pulmatrix's score of 0.30 indicating that NeuroSense Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroSense Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pulmatrix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Pulmatrix (PULM) Competitors

$1.61 +0.04 (+2.55%)

Closing price 07/16/2026 04:00 PM Eastern

Extended Trading

$1.60 -0.01 (-0.62%)

As of 07/16/2026 05:21 PM Eastern

Compare

PULM vs. MDCX, SKYE, ALVR, AYTU, and NRSN

Should you buy Pulmatrix stock or one of its competitors? MarketBeat compares Pulmatrix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pulmatrix include Medicus Pharma (MDCX), Skye Bioscience (SKYE), AlloVir (ALVR), Aytu BioPharma (AYTU), and NeuroSense Therapeutics (NRSN). These companies are all part of the "pharmaceutical products" industry.

How does Pulmatrix compare to Medicus Pharma?

Medicus Pharma (NASDAQ:MDCX) and Pulmatrix (NASDAQ:PULM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Pulmatrix's return on equity of -107.84% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicus Pharma	N/A	-3,137.84%	-311.33%
Pulmatrix	N/A	-107.84%	-91.58%

11.8% of Pulmatrix shares are held by institutional investors. 8.1% of Medicus Pharma shares are held by insiders. Comparatively, 0.6% of Pulmatrix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Medicus Pharma has a beta of -0.05, meaning that its stock price is 105% less volatile than the broader market. Comparatively, Pulmatrix has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market.

Pulmatrix has higher revenue and earnings than Medicus Pharma. Pulmatrix is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A
Pulmatrix	$7.81M	0.75	-$5.16M	-$1.23	N/A

In the previous week, Medicus Pharma had 2 more articles in the media than Pulmatrix. MarketBeat recorded 5 mentions for Medicus Pharma and 3 mentions for Pulmatrix. Medicus Pharma's average media sentiment score of 1.17 beat Pulmatrix's score of 0.30 indicating that Medicus Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medicus Pharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulmatrix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Medicus Pharma presently has a consensus target price of $9.00, suggesting a potential upside of 2,116.75%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Medicus Pharma is more favorable than Pulmatrix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Medicus Pharma and Pulmatrix tied by winning 7 of the 14 factors compared between the two stocks.

How does Pulmatrix compare to Skye Bioscience?

Pulmatrix (NASDAQ:PULM) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

Pulmatrix has higher revenue and earnings than Skye Bioscience. Pulmatrix is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmatrix	$7.81M	0.75	-$5.16M	-$1.23	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A

Skye Bioscience has a consensus price target of $8.50, indicating a potential upside of 1,252.21%. Given Skye Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Skye Bioscience is more favorable than Pulmatrix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

11.8% of Pulmatrix shares are held by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are held by institutional investors. 0.6% of Pulmatrix shares are held by company insiders. Comparatively, 6.2% of Skye Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Pulmatrix's return on equity of -107.84% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmatrix	N/A	-107.84%	-91.58%
Skye Bioscience	N/A	-217.27%	-162.39%

Pulmatrix has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.94, meaning that its share price is 194% more volatile than the broader market.

In the previous week, Pulmatrix and Pulmatrix both had 3 articles in the media. Skye Bioscience's average media sentiment score of 0.47 beat Pulmatrix's score of 0.30 indicating that Skye Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulmatrix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Skye Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Skye Bioscience beats Pulmatrix on 9 of the 14 factors compared between the two stocks.

How does Pulmatrix compare to AlloVir?

Pulmatrix (NASDAQ:PULM) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

AlloVir's return on equity of -71.03% beat Pulmatrix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmatrix	N/A	-107.84%	-91.58%
AlloVir	N/A	-71.03%	-61.27%

In the previous week, Pulmatrix had 3 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for Pulmatrix and 0 mentions for AlloVir. Pulmatrix's average media sentiment score of 0.30 beat AlloVir's score of 0.00 indicating that Pulmatrix is being referred to more favorably in the media.

Company	Overall Sentiment
Pulmatrix	Neutral
AlloVir	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Pulmatrix has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

Pulmatrix has higher revenue and earnings than AlloVir. Pulmatrix is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmatrix	$7.81M	0.75	-$5.16M	-$1.23	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

11.8% of Pulmatrix shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 0.6% of Pulmatrix shares are held by insiders. Comparatively, 32.1% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Pulmatrix beats AlloVir on 7 of the 12 factors compared between the two stocks.

How does Pulmatrix compare to Aytu BioPharma?

Pulmatrix (NASDAQ:PULM) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

Aytu BioPharma has a consensus price target of $10.75, indicating a potential upside of 397.69%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Aytu BioPharma is more favorable than Pulmatrix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Pulmatrix has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat Pulmatrix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmatrix	N/A	-107.84%	-91.58%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

In the previous week, Pulmatrix had 2 more articles in the media than Aytu BioPharma. MarketBeat recorded 3 mentions for Pulmatrix and 1 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 0.43 beat Pulmatrix's score of 0.30 indicating that Aytu BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Pulmatrix	Neutral
Aytu BioPharma	Neutral

11.8% of Pulmatrix shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 0.6% of Pulmatrix shares are held by company insiders. Comparatively, 4.9% of Aytu BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Pulmatrix has higher earnings, but lower revenue than Aytu BioPharma. Pulmatrix is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmatrix	$7.81M	0.75	-$5.16M	-$1.23	N/A
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A

Pulmatrix has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

Summary

Aytu BioPharma beats Pulmatrix on 10 of the 16 factors compared between the two stocks.

How does Pulmatrix compare to NeuroSense Therapeutics?

NeuroSense Therapeutics (NASDAQ:NRSN) and Pulmatrix (NASDAQ:PULM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

NeuroSense Therapeutics' return on equity of 0.00% beat Pulmatrix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Pulmatrix	N/A	-107.84%	-91.58%

NeuroSense Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market. Comparatively, Pulmatrix has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market.

Pulmatrix has higher revenue and earnings than NeuroSense Therapeutics. Pulmatrix is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
Pulmatrix	$7.81M	0.75	-$5.16M	-$1.23	N/A

NeuroSense Therapeutics currently has a consensus target price of $8.50, indicating a potential upside of 1,110.31%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Pulmatrix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Pulmatrix had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 3 mentions for Pulmatrix and 2 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 1.40 beat Pulmatrix's score of 0.30 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroSense Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulmatrix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 11.8% of Pulmatrix shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by insiders. Comparatively, 0.6% of Pulmatrix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

NeuroSense Therapeutics beats Pulmatrix on 10 of the 15 factors compared between the two stocks.

Get Pulmatrix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PULM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PULM vs. The Competition

Export

Metric	Pulmatrix	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.73M	$3.67B	$6.96B	$12.67B
Dividend Yield	N/A	2.20%	2.68%	8.87%
P/E Ratio	-1.31	21.07	27.21	24.05
Price / Sales	0.75	300.81	577.75	112.08
Price / Cash	N/A	146.26	49.25	59.89
Price / Book	0.66	8.39	10.78	6.23
Net Income	-$5.16M	$23.83M	$3.59B	$331.94M
7 Day Performance	-6.40%	-3.70%	-1.92%	-1.65%
1 Month Performance	7.33%	3.04%	2.24%	-1.03%
1 Year Performance	-74.57%	42.73%	23.86%	17.10%

Pulmatrix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PULM Pulmatrix	0.491 of 5 stars	$1.61 +2.5%	N/A	-73.6%	$5.73M	$7.81M	N/A	20	Analyst Downgrade
MDCX Medicus Pharma	3.5007 of 5 stars	$0.43 -2.6%	$9.00 +2,000.4%	-86.6%	$24.93M	N/A	N/A	N/A	News Coverage Positive News Short Interest Decrease Gap Up
SKYE Skye Bioscience	2.1592 of 5 stars	$0.70 0.0%	$8.50 +1,109.1%	-83.0%	$24.72M	N/A	N/A	11	Gap Up
ALVR AlloVir	N/A	$4.83 +3.9%	N/A	+100.8%	$24.36M	N/A	N/A	110
AYTU Aytu BioPharma	2.3151 of 5 stars	$2.18 -3.1%	$10.75 +393.1%	-6.9%	$24.15M	$66.38M	N/A	160	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PULM) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pulmatrix (PULM) Competitors

PULM vs. MDCX, SKYE, ALVR, AYTU, and NRSN

How does Pulmatrix compare to Medicus Pharma?

Summary

How does Pulmatrix compare to Skye Bioscience?

Summary

How does Pulmatrix compare to AlloVir?

Summary

How does Pulmatrix compare to Aytu BioPharma?

Summary

How does Pulmatrix compare to NeuroSense Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PULM vs. The Competition

Pulmatrix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pulmatrix (PULM) Competitors

PULM vs. MDCX, SKYE, ALVR, AYTU, and NRSN

How does Pulmatrix compare to Medicus Pharma?

Is MDCX or PULM more profitable?

Do insiders and institutionals hold more shares of MDCX or PULM?

Which has more volatility & risk, MDCX or PULM?

Which has higher earnings & valuation, MDCX or PULM?

Does the media favor MDCX or PULM?

Do analysts rate MDCX or PULM?

Summary

How does Pulmatrix compare to Skye Bioscience?

Which has better valuation & earnings, PULM or SKYE?

Do analysts rate PULM or SKYE?

Do institutionals and insiders believe in PULM or SKYE?

Is PULM or SKYE more profitable?

Which has more risk & volatility, PULM or SKYE?

Does the media refer more to PULM or SKYE?

Summary

How does Pulmatrix compare to AlloVir?

Is PULM or ALVR more profitable?

Does the media refer more to PULM or ALVR?

Do analysts rate PULM or ALVR?

Which has more risk and volatility, PULM or ALVR?

Which has higher earnings and valuation, PULM or ALVR?

Do institutionals & insiders have more ownership in PULM or ALVR?

Summary

How does Pulmatrix compare to Aytu BioPharma?

Do analysts rate PULM or AYTU?

Is PULM or AYTU more profitable?

Does the media refer more to PULM or AYTU?

Do institutionals and insiders have more ownership in PULM or AYTU?

Which has preferable valuation and earnings, PULM or AYTU?

Which has more volatility and risk, PULM or AYTU?

Summary

How does Pulmatrix compare to NeuroSense Therapeutics?

Is NRSN or PULM more profitable?

Which has more volatility and risk, NRSN or PULM?

Which has higher valuation & earnings, NRSN or PULM?

Do analysts rate NRSN or PULM?

Does the media prefer NRSN or PULM?

Do insiders & institutionals have more ownership in NRSN or PULM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PULM vs. The Competition

Pulmatrix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools